Boston Scientific Corporation (BSX) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Boston Scientific published the results on October 28, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Boston Scientific reports EPS two ways: GAAP, under the accounting rules every US filer follows, and adjusted, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• A cybersecurity incident first reported on August 26, 2026 disrupted Boston Scientific's manufacturing and order processing worldwide. The 10-Q says it materially impacted third quarter results.
• The business-level rows (Endoscopy through Interventional Oncology & Embolization) come from the Q3 2026 Form 10-Q; the release gives MedSurg and Cardiovascular totals and the three MedSurg businesses.

Source: Boston Scientific Q3 2026 results, October 28, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Boston Scientific splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Boston Scientific's MedSurg revenue was $1.7 billion in Q3 2026, up 1% from $1.7 billion in Q3 2025, 34% of total revenue.
• Boston Scientific's Cardiovascular revenue was $3.4 billion in Q3 2026, up 2% from $3.3 billion in Q3 2025, 66% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Boston Scientific said:

“The company now estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 4.25 percent on a reported basis and approximately 3.75 percent on an organic basis.”

“The company now estimates adjusted EPS, excluding certain charges (credits), of $3.16 to $3.18.”

“The company estimates net sales to decline in the fourth quarter of 2026, versus the prior year period, by approximately (3.0) to (1.0) percent on a reported and organic basis.”

“The company estimates adjusted EPS, excluding certain charges (credits), of $0.77 to $0.79.”

Source: Boston Scientific Q3 2026 release, Oct 28, 2026.

This is the company's own guidance as of Oct 28, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the BSX forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP net sales and diluted EPS, each as first reported in that quarter's release. Q1 2026 EPS of $0.90 includes a $383 million discrete tax benefit.

We do not hold a confirmed date for Boston Scientific's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 28, 2026

Boston Scientific reports two segments. Cardiovascular brought in $3,406 million of the $5,138 million in Q3 2026 net sales, and MedSurg (Endoscopy, Urology and Neuromodulation) brought in $1,733 million. Total net sales rose 1.5 percent on a reported, operational and organic basis, with Cardiovascular up 1.9 percent and MedSurg up 0.6 percent reported. (Boston Scientific Q3 2026 release, Oct 28, 2026)

Inside Cardiovascular, Boston Scientific's 10-Q shows Interventional Cardiology & Vascular Therapies at $1,273 million against $1,135 million a year earlier, led by the AGENT Drug-Coated Balloon. Electrophysiology fell to $816 million from $865 million and Watchman to $482 million from $512 million. The 10-Q names increased competition in Electrophysiology and a deceleration in the left atrial appendage closure (LAAC) market, which affected WATCHMAN procedures. (Boston Scientific Form 10-Q, Q3 2026, Nov 2, 2026)

Boston Scientific's 10-Q says a cybersecurity incident disrupted its information technology systems worldwide, affecting its ability to manufacture, process and ship customer orders, and materially impacted third quarter results. Endoscopy sales of $741 million declined because of that disruption and volume-based procurement (VBP) in China, and Urology sales of $661 million fell on the same disruption, VBP in the stone franchise and disruption in sacral neuromodulation. Neuromodulation grew 13.1 percent to $331 million, led by the Nalu Peripheral Nerve Stimulation System and the Intracept system. (Boston Scientific Form 10-Q, Q3 2026, Nov 2, 2026; Boston Scientific Q3 2026 release, Oct 28, 2026)

The U.S. accounted for $3,309 million of Boston Scientific's Q3 2026 net sales, up 0.5 percent. EMEA sales were $829 million, up 4.4 percent reported and 6.1 percent operational; APAC sales were $797 million, down 0.6 percent reported; and Latin America and Canada sales were $203 million, up 16.0 percent reported. (Boston Scientific Q3 2026 release, Oct 28, 2026)

Boston Scientific's 10-K says no single customer accounted for more than ten percent of net sales in 2025, though large group purchasing organizations and hospital networks hold buying power. Full-year 2025 net sales were $20,074 million, and the 10-K credits that year's growth largely to the Farapulse Pulsed Field Ablation System, which launched in the U.S. in early 2024. (Boston Scientific Form 10-K, 2025, Feb 17, 2026)

Boston Scientific's GAAP diluted EPS was $0.40 in Q3 2026, against adjusted EPS of $0.73. The release's reconciliation lists the largest per-share items excluded from adjusted EPS: amortization expense ($0.14), restructuring and restructuring-related charges ($0.05), deferred tax expenses ($0.05), acquisition and divestiture-related charges ($0.04), litigation-related charges ($0.04) and intangible asset impairment charges ($0.02). (Boston Scientific Q3 2026 release, Oct 28, 2026)

Gross margin fell to 66.7% from 69.9% a year earlier, and Boston Scientific's 10-Q attributes 1.7 points of that to abnormal production variances from the cybersecurity incident, from idle production time. The quarter also carried $81 million of litigation-related net charges, against none in Q3 2025. The reported tax rate was 20.8%, against a 17.6% rate from continuing operations. (Boston Scientific Form 10-Q, Q3 2026, Nov 2, 2026)

Diluted weighted-average shares were 1,452.0 million, down from 1,495.5 million. In May 2026 Boston Scientific paid $2.000 billion upfront to JPMorgan under an accelerated share repurchase agreement and received an initial delivery of approximately 30 million shares, and as of September 30, 2026 it had $3.000 billion remaining under its repurchase authorization. (Boston Scientific Q3 2026 release, Oct 28, 2026; Boston Scientific Form 10-Q, Q3 2026, Nov 2, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Boston Scientific gives guidance in its release. After Q3 2026 it estimated full-year 2026 net sales growth of approximately 4.25 percent reported and 3.75 percent organic, and full-year adjusted EPS of $3.16 to $3.18. For Q4 2026 it estimated net sales would decline by approximately (3.0) to (1.0) percent, with adjusted EPS of $0.77 to $0.79. (Boston Scientific Q3 2026 release, Oct 28, 2026)

Boston Scientific does not give GAAP EPS guidance, saying it cannot predict items such as intangible asset impairment, acquisition-related, restructuring and litigation-related charges with reasonable certainty. (Boston Scientific Q3 2026 release, Oct 28, 2026)

A consensus figure is the average of the models published by the analysts who cover Boston Scientific, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Boston Scientific's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning BSX is on is BSX a buy or a sell?, what analysts expect next is on the BSX forecast, and what the company does is on the Boston Scientific Corporation (BSX) stock page.

Every number on this page can be traced to a document Boston Scientific published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.